The company sees increased traction in its core segment of studies of evaluating the generic versions of proprietary drugs that go off patent, as well bright prospects from clinical trials of biosimilars and novel drugs.Veeda Clinical Research filing for Rs 500 crore - Rs 700 crore IPO, sources say
The company sees increased traction in its core segment of studies of evaluating the generic versions of proprietary drugs that go off patent, as well bright prospects from clinical trials of biosimilars and novel drugs.
Subscribe to:
Post Comments (Atom)
-
The company did not export units last month while it had dispatched 804 Etios units in in June 2019.
-
Google has tried for years to get Samsung, the world#39;s leading mobile device maker by units sold, to drop its own services and give grea...
-
The company, one of the leading manufacturers of soda ash, had initiated the process of carving out its textiles business into GHCL Textile...
No comments:
Post a Comment